In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Shake Up At Endo Pharma

Executive Summary

Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.
Advertisement

Related Content

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Endo Dives Deeper Into Devices With AMS Acquisition
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010
Pharma: Serious About Change?
CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena
Endo: Accessing Primary Care through Specialist Marketing
Endo: Accessing Primary Care through Specialist Marketing
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
J&J/Centocor: One Rx Treats a Range of Growth Ailments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel